Posted by Michael Wonder on 01 Jul 2023
Sandoz to launch Hyrimoz (adalimumab-adaz) high concentration formulation, marking Sandoz entrance into US immunology space
1 July 2023 - Hyrimoz (adalimumab-adaz) high concentration formulation biosimilar offers US patients reduced injection volume in citrate free formulation.
Sandoz today announced that the citrate-free high-concentration formulation of its biosimilar Hyrimoz (adalimumab-adaz) injection will be available in the United States starting July 1.
